Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
LXEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.32 - $19.50
Previous CloseN/A
Volume22.32K
Average Volume (3M)750.38K
Market Cap
$136.44M
Enterprise Value$106.05M
Total Cash (Recent Filing)$77.33M
Total Debt (Recent Filing)$13.48M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 08, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.09
Shares Outstanding33,197,000
10 Day Avg. Volume1,259,402
30 Day Avg. Volume750,382
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.54
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$20.50Price Target Upside398.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Lexeo Therapeutics, Inc. News
PremiumCompany Announcements
Lexeo Therapeutics Advances Genetic Medicine Initiatives
PremiumCompany Announcements
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsAll four patients measured in the Phase 1/2 demonstrated increases in frataxin.
Regulatory AlignmentLexeo reported further positive news on its alignment with the FDA for pivotal development of LX2006 in Friedreich's ataxia cardiomyopathy.
Regulatory ApprovalData from Cohort 3 could potentially exceed FDA's requirements for approval, enhancing the regulatory chances for Lexeo.
Bears Say
Development ChallengesWhile the data is considered positive, the AD development landscape has been fraught with challenges.
Financial PerformanceThird-quarter financials did not meet consensus estimates, reporting a higher loss than expected.
Market SentimentShares are down 59% year-to-date, indicating negative market sentiment despite positive clinical updates.
---
Ownership Overview
1.60% Insiders
11.26% Mutual Funds
44.80% Other Institutional Investors
35.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $2.32 and its highest was $19.50 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $136.44M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Mar 24, 2025. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.807 by $0.027.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.78.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 33,197,000 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.807. Following the earnings report the stock price went up 50.923%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
---
Lexeo Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (398.78% Upside)
$20.50 (398.78% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.08%
12-Months-Change
Fundamentals
Return on Equity
-85.37%
Trailing 12-Months
Asset Growth
4.71%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
---
LXEO Stock 12 Month Forecast
Average Price Target
$20.50
▲(398.78% Upside)
Technical Analysis
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LXEO
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-46.63%
reiterated a buy rating 6 days ago
Copying Luca Issi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.63% per trade.
---